ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2026, Vol. 35 ›› Issue (2): 147-152.DOI: 10.3969/j.issn.1006-298X.2026.02.008

• 论著 • 上一篇    下一篇

罗沙司他对维持性血液透析患者认知功能的影响 --- 基于倾向性评分的队列研究

  

  • 出版日期:2026-04-28 发布日期:2026-04-23

Roxadustat on cognitive function in maintenance hemodialysis patients-propensity score-matched cohort study

  • Online:2026-04-28 Published:2026-04-23

摘要: 目的:探讨罗沙司他对维持性血液透析患者认知功能的影响及其机制。方法:选取 2023 年 4 月至 2024 年 4 月在四家三级医院行规律血液透析的患者 355 例,依据贫血药物将其分为罗沙司他组和促红细胞生成素 (EPO) 组。收集两组患者一般资料、实验室指标、采用 ELISA 检测血浆缺氧诱导因子 1α(HIF-1α)、解整合素 - 金属蛋白酶 10 (ADAM10)、β 淀粉样蛋白 (Aβ) 水平;蒙特利尔认知评估量表 (MoCA) 评估患者认知功能;采用倾向性匹配评分均衡基线;利用中介效应模型分析罗沙司他是否通过 HIF-1α/ADAM10/Aβ 通路影响患者的认知功能。结果:倾向性匹配评分后两组患者基线的血红蛋白、年龄、教育年限、高血压、糖尿病、透析月龄差异均无统计学意义;与基线相比,罗沙司他组随访 6 个月后 MoCA 评分总分、视空间及执行力、语言、抽象、延迟回忆得分高于基线 (P<0.05), 延迟回忆得分罗沙司他组高于 EPO 组 (P=0.016); 罗沙司他对 MoCA 评分的影响通过 HIF-1α、ADAM10、Aβ 中介效应估计值效应不显著。结论:罗沙司他组患者治疗 6 个月后 MoCA 评分较基线显著改善,其延迟回忆领域的改善优于 EPO 组,作用机制仍有待深入研究。

关键词: 维持性血液透析, 罗沙司他, 认知功能, 队列研究

Abstract: Objective:To investigate the Effects of Roxadustat on Cognitive Function in Patients Undergoing Maintenance Hemodialysis and Its Potential Mechanisms. Methods:A total of 355 patients undergoing regular hemodialysis at four tertiary hospitals between April 2023 and April 2024 were enrolled.They were divided into the Roxadustat group and the erythropoietin group based on their anemia medication.General information,laboratory indexes,plasma HIF-1α,ADAM10,and Aβ levels were collected from the two groups,and plasma HIF-1α,ADAM10,and Aβ levels were detected by ELISA;patients'cognitive functions were assessed by the MoCA scale.Propensity-matched scores were used to balance the imbalance between groups at baseline,and mediated effect models were used to analyze whether Roxadustat affected patients'cognitive functions through the HIF-1α/ADAM10/Aβ pathway. Results:After propensity score matching,there were no statistically significant differences between the two patient groups in baseline hemoglobin levels, age, years of education, hypertension, diabetes, or duration of dialysis (P>0.05); compared with baseline, the total MoCA score,visuospatial and executive,verbal,abstract,and delayed recall scores were higher in the Roxadustat group than in the baseline after 6 months of follow-up, with statistically significant differences (P<0.05); the delayed recall score was higher in the Roxadustat group than in the Erythropoietin group,and the difference was statistically significant (P=0.016); the ffet of Roxadustat on MoCA scores was not signiicant through the estimated value of the mediating effect of HIF-1α,ADAM10,and Aβ. Conclusion:Patients in the Roxadustat group demonstrated significant improvement in MoCA scores after 6 months of treatment compared to baseline,with superior gains in the delayed recall domain relative to the erythropoietin group.